


## PHARMACEUTICAL 2022

## Tharimmune Inc. Rank 446 of 466





## PHARMACEUTICAL 2022

## Tharimmune Inc. Rank 446 of 466

The relative strengths and weaknesses of Tharimmune Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Tharimmune Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 35% points. The greatest weakness of Tharimmune Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 247% points.

The company's Economic Capital Ratio, given in the ranking table, is -346%, being 424% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	622
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,534
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	773
Other Net Income	1,001
Other Revenues	0
Property and Equipment	0
Research and Development	1,843
Selling, General and Administrative Expense	1,365

Output Variable	Value in 1000 USD
Assets	622
Liabilities	5,307
Expenses	3,208
Revenues	0
Stockholders Equity	-4,685
Net Income	-2,207
Comprehensive Net Income	-2,207
Economic Capital Ratio	-346%

